STOCK TITAN

Therapeutics, Inc. (FULC) 8.22% stake disclosed by Nantahala Capital

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Therapeutics, Inc. (par value $0.001 per share, CUSIP 359616109).

As of June 30, 2026, the reporting persons may be deemed beneficial owners of 5,475,040 shares, representing 8.22% of the outstanding common stock. These shares are held by funds and separately managed accounts under Nantahala’s control. Each reporting person has shared voting power and shared dispositive power over 5,475,040 shares and no sole voting or dispositive power. Harkey and Mack file as control persons with respect to shares beneficially owned by Nantahala, an investment adviser.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 5,475,040 shares Common stock beneficially owned as of June 30, 2026
Percent of class 8.22% Percentage of Therapeutics, Inc. common stock as of June 30, 2026
Shared voting power 5,475,040 shares Shares over which each reporting person has shared voting power
Shared dispositive power 5,475,040 shares Shares over which each reporting person has shared dispositive power
CUSIP 359616109 CUSIP number for Therapeutics, Inc. common stock
Par value $0.001 per share Par value of Therapeutics, Inc. common stock
beneficial owner financial
"Nantahala may be deemed to be the beneficial owner of 5,475,040 Shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting power financial
"Shared Voting Power 5,475,040.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 5,475,040.00"
Schedule 13G regulatory
"Each of Messrs. Harkey and Mack is filing this as a control person"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
control person financial
"each of Messrs. Harkey and Mack is filing this as a control person"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.

FAQ

What percentage of FULC common stock does Nantahala Capital Management report owning?

Nantahala Capital Management and its principals report beneficial ownership of 8.22% of Therapeutics, Inc. common stock. This percentage is based on 5,475,040 shares beneficially owned as of June 30, 2026, relative to the company’s outstanding shares.

How many FULC shares are beneficially owned by Nantahala and its principals?

Nantahala and its principals report beneficial ownership of 5,475,040 shares of Therapeutics, Inc. common stock. These shares are held by funds and separately managed accounts under Nantahala’s control as of June 30, 2026.

What type of SEC filing is this Schedule 13G for FULC?

This is a Schedule 13G filing reporting passive beneficial ownership in Therapeutics, Inc. common stock. It discloses the holdings and voting/dispositive powers of Nantahala Capital Management and its principals as of June 30, 2026.

What voting and dispositive powers do the FULC reporting persons have over their shares?

Each reporting person has 0 shares with sole voting or dispositive power and 5,475,040 shares with shared voting and shared dispositive power. This reflects coordinated control over the same block of Therapeutics, Inc. common stock.

Who are the reporting persons in the FULC Schedule 13G filing?

The reporting persons are Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack. Harkey and Mack are managing members of Nantahala and file as control persons regarding the shares beneficially owned by Nantahala.

As of what date are the FULC beneficial ownership figures reported?

All ownership figures are reported as of June 30, 2026. On that date, the reporting persons may be deemed to beneficially own 5,475,040 shares, representing 8.22% of Therapeutics, Inc. common stock, with shared voting and dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





359616109

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2026
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2026
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2026